Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
News|Articles|January 20, 2026
State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment
Author(s)Christopher Cole
A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.
This article was originally published by
Related to this article
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Orbis Medicines strikes a partnership with Novo, Dualitas Therapeutics enters collaboration with Roche, and Aethlon Medical has agreed to merge with North Immunology.
Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
GSK agrees to acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences, while Sanofi is offloading 20 mature medicines and three manufacturing sites to Cheplapharm.